Seer, Inc. (SEER) Research
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Market snapshot
- Symbol
- SEER
- Price
- $1.74
- Day change
- +1.16%
- Market cap
- $95.7M
- P/E ratio
- -1.38x
- 52-week range
- 1.65-2.41
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $4.00
Recent news
- Seer Shares Jump On Takeover Proposal
Seer, Inc. (NASDAQ: SEER) shares are trading higher Monday after the company announced that the Radoff-JEC Group submitted a non-binding proposal to acquire the company.
Peer companies
Recent insider activity
- Horn David R. — S-Sale (7303 shares) on 2026-05-20
- Bazarko Anthony R. — A-Award (225000 shares) on 2026-05-08
- Bazarko Anthony R. — A-Award (75000 shares) on 2026-05-08
- Bazarko Anthony R. — trade (0 shares) on 2026-05-04
- Horn David R. — S-Sale (7743 shares) on 2026-02-18
Open Seer, Inc. (SEER) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.